Cargando…
Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC
There is a lack of effective programmed cell death protein 1 (PD-1)‐targeted immunotherapy with good tolerability in patients with advanced hepatocellular carcinoma (HCC) and severely compromised liver function. We assessed patient outcomes after combined camrelizumab and molecular targeted therapy...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264531/ https://www.ncbi.nlm.nih.gov/pubmed/36840762 http://dx.doi.org/10.1007/s00262-023-03404-8 |
_version_ | 1785058344191393792 |
---|---|
author | Li, Ting Guo, Jiang Liu, Yushen Du, Zhaoqing Guo, Zhaoyang Fan, Yangwei Cheng, Long Zhang, Yue Gao, Xu Zhao, Yunyu He, Xinyuan Wu, Wenhua Gao, Ning Wu, Yinying Li, Jie Zhang, Yu Kang, Wen Cai, Zhifang Wang, Wenjun Li, Xiaopeng Zan, Ying Nguyen, Mindie H. Ji, Fanpu |
author_facet | Li, Ting Guo, Jiang Liu, Yushen Du, Zhaoqing Guo, Zhaoyang Fan, Yangwei Cheng, Long Zhang, Yue Gao, Xu Zhao, Yunyu He, Xinyuan Wu, Wenhua Gao, Ning Wu, Yinying Li, Jie Zhang, Yu Kang, Wen Cai, Zhifang Wang, Wenjun Li, Xiaopeng Zan, Ying Nguyen, Mindie H. Ji, Fanpu |
author_sort | Li, Ting |
collection | PubMed |
description | There is a lack of effective programmed cell death protein 1 (PD-1)‐targeted immunotherapy with good tolerability in patients with advanced hepatocellular carcinoma (HCC) and severely compromised liver function. We assessed patient outcomes after combined camrelizumab and molecular targeted therapy in a multicenter cohort study in China. The study included 99 patients with advanced HCC (58 Child-Pugh A and 41 Child-Pugh B), 84 of them received camrelizumab combined with molecular targeted therapy from January 10, 2019, to March 31, 2021. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) were assessed. The median follow-up was 12.1 months. For patients with Child-Pugh B, the OS probability at 12-months, ORR and DCR were 49.7%, 31.7% and 65.9%, respectively, and the median PFS was 5.1 months [95% confidence interval (CI) 3.0–7.1], which were comparable with Child-Pugh A patients, although median OS was shorter in Child‐Pugh B patients (20.5 vs.13.4 months, P = 0.12). In multivariate analysis, macrovascular infiltration (MVI), but not sex, age, hepatitis B virus etiology, extrahepatic metastasis, Child-Pugh B, or AFP > 400 ng/ml, was associated with 12-months OS [hazard ratio (HR) 2.970, 95% CI 1.276–6.917, P = 0.012] and ORR (HR 2.906, 95% CI 1.18–7.16, P = 0.020). Grade 3/4 immune-related AEs occurred in 26.8% of Child-Pugh B patients, including one potentially treatment-related death. In both groups, the most common AEs were immune thrombocytopenia and hepatotoxicity. Camrelizumab combined with targeted therapy showed favorable effectiveness and tolerability with manageable toxicities in Chinese HCC patients, regardless of Child-Pugh A/B liver function. MVI was associated with suboptimal immunotherapy response and poor prognosis. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00262-023-03404-8. |
format | Online Article Text |
id | pubmed-10264531 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-102645312023-06-15 Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC Li, Ting Guo, Jiang Liu, Yushen Du, Zhaoqing Guo, Zhaoyang Fan, Yangwei Cheng, Long Zhang, Yue Gao, Xu Zhao, Yunyu He, Xinyuan Wu, Wenhua Gao, Ning Wu, Yinying Li, Jie Zhang, Yu Kang, Wen Cai, Zhifang Wang, Wenjun Li, Xiaopeng Zan, Ying Nguyen, Mindie H. Ji, Fanpu Cancer Immunol Immunother Research There is a lack of effective programmed cell death protein 1 (PD-1)‐targeted immunotherapy with good tolerability in patients with advanced hepatocellular carcinoma (HCC) and severely compromised liver function. We assessed patient outcomes after combined camrelizumab and molecular targeted therapy in a multicenter cohort study in China. The study included 99 patients with advanced HCC (58 Child-Pugh A and 41 Child-Pugh B), 84 of them received camrelizumab combined with molecular targeted therapy from January 10, 2019, to March 31, 2021. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) were assessed. The median follow-up was 12.1 months. For patients with Child-Pugh B, the OS probability at 12-months, ORR and DCR were 49.7%, 31.7% and 65.9%, respectively, and the median PFS was 5.1 months [95% confidence interval (CI) 3.0–7.1], which were comparable with Child-Pugh A patients, although median OS was shorter in Child‐Pugh B patients (20.5 vs.13.4 months, P = 0.12). In multivariate analysis, macrovascular infiltration (MVI), but not sex, age, hepatitis B virus etiology, extrahepatic metastasis, Child-Pugh B, or AFP > 400 ng/ml, was associated with 12-months OS [hazard ratio (HR) 2.970, 95% CI 1.276–6.917, P = 0.012] and ORR (HR 2.906, 95% CI 1.18–7.16, P = 0.020). Grade 3/4 immune-related AEs occurred in 26.8% of Child-Pugh B patients, including one potentially treatment-related death. In both groups, the most common AEs were immune thrombocytopenia and hepatotoxicity. Camrelizumab combined with targeted therapy showed favorable effectiveness and tolerability with manageable toxicities in Chinese HCC patients, regardless of Child-Pugh A/B liver function. MVI was associated with suboptimal immunotherapy response and poor prognosis. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00262-023-03404-8. Springer Berlin Heidelberg 2023-02-25 2023 /pmc/articles/PMC10264531/ /pubmed/36840762 http://dx.doi.org/10.1007/s00262-023-03404-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Li, Ting Guo, Jiang Liu, Yushen Du, Zhaoqing Guo, Zhaoyang Fan, Yangwei Cheng, Long Zhang, Yue Gao, Xu Zhao, Yunyu He, Xinyuan Wu, Wenhua Gao, Ning Wu, Yinying Li, Jie Zhang, Yu Kang, Wen Cai, Zhifang Wang, Wenjun Li, Xiaopeng Zan, Ying Nguyen, Mindie H. Ji, Fanpu Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC |
title | Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC |
title_full | Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC |
title_fullStr | Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC |
title_full_unstemmed | Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC |
title_short | Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC |
title_sort | effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced hcc |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264531/ https://www.ncbi.nlm.nih.gov/pubmed/36840762 http://dx.doi.org/10.1007/s00262-023-03404-8 |
work_keys_str_mv | AT liting effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc AT guojiang effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc AT liuyushen effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc AT duzhaoqing effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc AT guozhaoyang effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc AT fanyangwei effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc AT chenglong effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc AT zhangyue effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc AT gaoxu effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc AT zhaoyunyu effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc AT hexinyuan effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc AT wuwenhua effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc AT gaoning effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc AT wuyinying effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc AT lijie effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc AT zhangyu effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc AT kangwen effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc AT caizhifang effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc AT wangwenjun effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc AT lixiaopeng effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc AT zanying effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc AT nguyenmindieh effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc AT jifanpu effectivenessandtolerabilityofcamrelizumabcombinedwithmoleculartargetedtherapyforpatientswithunresectableoradvancedhcc |